Catalyst Pharmaceuticals Inc (CPRX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 84.10% | 82.32% | 82.44% | 84.54% | 84.67% | 86.41% | 85.86% | 85.01% | 83.94% | 84.07% | 84.64% | 84.98% | 84.46% | 85.47% | 85.84% | 85.38% | 85.69% | 85.98% | 85.74% | 85.55% |
| Operating profit margin | 39.68% | 37.78% | 19.77% | 19.04% | 21.80% | 21.79% | 45.62% | 46.82% | 47.54% | 43.69% | 42.64% | 39.00% | 37.20% | 36.14% | 36.22% | 33.63% | 34.69% | 34.43% | 35.77% | 36.57% |
| Pretax margin | 43.98% | 41.00% | 21.53% | 20.98% | 23.73% | 23.20% | 47.81% | 48.57% | 48.89% | 44.08% | 42.58% | 39.19% | 37.40% | 36.38% | 36.44% | 33.91% | 35.18% | 35.18% | 36.80% | 37.89% |
| Net profit margin | 33.33% | 31.01% | 15.69% | 15.83% | 17.93% | 17.81% | 38.14% | 38.76% | 38.79% | 34.90% | 31.97% | 29.31% | 28.03% | 31.16% | 58.80% | 60.11% | 62.97% | 60.48% | 34.87% | 36.09% |
Catalyst Pharmaceuticals Inc has shown a consistent gross profit margin ranging from 82.32% to 86.41% over the past few years, with a slight decline in the most recent quarter. This indicates that the company's ability to generate revenue after accounting for the cost of goods sold has remained relatively high, although there has been some fluctuation in recent periods.
In terms of operating profit margin, Catalyst Pharmaceuticals Inc has experienced more variability, ranging from 19.04% to 47.54% over the same period. The company's operating efficiency has shown significant improvement in some quarters, but there have been notable declines as well. The most recent data shows a decline in the operating profit margin, which may raise concerns about the company's operational effectiveness.
The pretax margin for Catalyst Pharmaceuticals Inc has also fluctuated widely, ranging from 20.98% to 48.89% over the past few years. Despite some quarters with high profitability before tax, there have been periods with lower margins. The trend shows a recent decline in pretax margin, which may indicate challenges in managing expenses and optimizing revenue generation.
Lastly, the net profit margin for Catalyst Pharmaceuticals Inc has varied from 15.69% to 62.97% over the same period, showing significant fluctuations in profitability after accounting for all expenses. The data reveals a recent decline in net profit margin, suggesting potential issues with cost management or revenue growth.
In summary, while Catalyst Pharmaceuticals Inc has maintained a relatively high gross profit margin, the company has experienced fluctuations in operating, pretax, and net profit margins. The recent downward trends in profitability ratios raise potential concerns about the company's financial performance and efficiency.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 22.92% | 22.54% | 12.16% | 12.11% | 18.40% | 18.37% | 31.14% | 29.49% | 27.11% | 25.15% | 27.19% | 24.27% | 22.03% | 21.62% | 21.98% | 20.49% | 21.47% | 23.27% | 32.60% | 36.91% |
| Return on assets (ROA) | 19.25% | 18.50% | 9.65% | 10.07% | 15.13% | 15.01% | 26.03% | 24.41% | 22.12% | 20.09% | 20.39% | 18.24% | 16.60% | 18.64% | 35.68% | 36.62% | 38.98% | 40.88% | 31.78% | 36.43% |
| Return on total capital | 18.50% | 17.17% | 12.53% | 13.92% | 20.63% | 19.66% | 34.87% | 33.79% | 33.65% | 31.01% | 30.08% | 27.13% | 25.26% | 24.18% | 24.27% | 22.64% | 24.37% | 26.00% | 38.49% | 43.52% |
| Return on equity (ROE) | 22.52% | 21.61% | 11.20% | 11.60% | 18.41% | 17.80% | 30.79% | 29.79% | 27.65% | 24.78% | 22.60% | 20.46% | 19.09% | 20.95% | 39.49% | 40.43% | 44.21% | 45.63% | 37.56% | 43.09% |
The profitability ratios of Catalyst Pharmaceuticals Inc show fluctuating trends over the periods provided.
1. Operating return on assets (Operating ROA) reflects the company's ability to generate operating profits from its assets. The ratio ranged from 18.37% to 36.91% during the period, peaking at 36.91% on March 31, 2020 and steadily declining to 12.11% on March 31, 2024, before slightly recovering. This downward trend indicates a decreasing efficiency in generating operating profits as a percentage of total assets.
2. Return on assets (ROA) measures the overall profitability of the company relative to its total assets. The ratio ranged from 9.65% to 40.88% over the period, with varying fluctuations. ROA peaked at 40.88% on September 30, 2020, and reached its lowest point of 9.65% on June 30, 2024. This indicates inconsistent profitability in relation to the company's total assets.
3. Return on total capital indicates the return generated on the total invested capital, including debt and equity. The ratio fluctuated from 12.53% to 43.52% during the period, with the highest return of 43.52% on March 31, 2020, and the lowest return of 12.53% on June 30, 2024. This demonstrates varying effectiveness in generating returns on the total capital employed over time.
4. Return on equity (ROE) represents the return generated on shareholders' equity. The ratio varied from 11.20% to 45.63% throughout the period. The highest ROE was recorded on September 30, 2020, while the lowest was on June 30, 2024. This fluctuation indicates the company's ability to generate profits for shareholders has been inconsistent.
In summary, Catalyst Pharmaceuticals Inc's profitability ratios have shown mixed trends over the period, indicating fluctuations in operational efficiency, overall profitability, return on total capital, and return on equity. Further analysis and contextual information would be necessary to understand the factors driving these fluctuations and to assess the company's overall financial health and performance.